2.01 Selinexor, ECHELON-2, Parachutes, Tumor-Treating Fields, & MedTwitter

OncologyMedicineHealth Policy
Written By Kerrington .

Welcome to season 2! We're starting this season off with a little bit of everything: a critique of the FDA's accelerated approval of selinexor for penta-refractory multiple myeloma; an interview with Dr. John Reneau of Ohio State University on ECHELON-2 (brentuximab vedotin in t-cell lymphomas); an interview with Dr. Michael Hayes of Kaiser Permanente on parachutes in medicine plus the relationship between conflict of interest and editorial stance on tumor-treating fields for glioblastoma multiforme; and an interview with Dr. Stacie Dusetzina - a leading researcher in health care policy and the cost of cancer drugs, and an avid Twitter user - of Vanderbilt University on #MedTwitter.

Kerrington .
Previous

2.02 BONUS! Improving Access to Prescription Drugs through Policy Change with Dr. Stacie Dusetzina
Next

1.68 Voxeletor with Dr. Olson & Humanizing Cancer, Defining Cancer, and more with Dr. David Steensma